Although a randomized clinical phase III trial23 showed that neutralizing CGRP did not affect joint pain in patients with osteoarthritis, pharmacological targeting of CGRP or its receptor may thus result in reduced osteophyte formation and maturation. This evidence concerns the gene CALCA and osteoarthritis.